Clinical and Experimental Medicine最新文献

{"title":"MicroRNAs at the crossroads of exercise and ferroptosis: a regulatory bridge.","authors":"Zhao Lin, Zhang Feng","doi":"10.1007/s10238-025-01766-0","DOIUrl":"10.1007/s10238-025-01766-0","url":null,"abstract":"<p><p>Ferroptosis is a unique form of regulated cell death characterized by iron-dependent lipid peroxidation. MicroRNAs (miRNAs) are pivotal in modulating ferroptosis by targeting essential molecules, including SLC7A11, GPX4, ACSL4, FSP1, and several iron-handling proteins, thereby influencing cellular susceptibility to oxidative damage. Exercise-responsive miRNAs-encompassing both tissue-specific and circulating miRNAs-regulate angiogenesis, inflammation, mitochondrial biogenesis, metabolic homeostasis, and cellular stress responses. Recent research suggests that specific miRNAs, such as miR-124, miR-9, miR-23, and miR-378, are relevant to both exercise adaptation and ferroptosis. This indicates a potential molecular connection between improved muscular performance and the mitigation of excessive iron-induced oxidative stress. These overlapping miRNAs are hypothesized to enhance antioxidant defenses, regulate iron transport, and maintain mitochondrial function during repeated redox stressors, such as those encountered during strenuous physical activity. However, research gaps remain regarding tissue specificity, longitudinal alterations in miRNA expression, and the precise extent to which miRNAs promote cytoprotection against ferroptosis in exercised tissues. Future directions encompass comprehensive time-course research, interventional experiments utilizing miRNA mimics or antagomiRs, and clinical trials to substantiate the therapeutic potential of these interactions. Integrating core findings from ferroptosis research with exercise physiology may lead to innovative strategies to enhance oxidative resilience and reduce cell death across various illness scenarios.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"234"},"PeriodicalIF":3.2,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of prognostic factors affecting TA-TMA patients: a single-center retrospective study.","authors":"Jile Liu, Haotian Meng, Tao Zhang, Xiu Liu, Mingfeng Zhao","doi":"10.1007/s10238-025-01774-0","DOIUrl":"10.1007/s10238-025-01774-0","url":null,"abstract":"<p><strong>Objective: </strong>Transplantation-associated thrombotic microangiopathy (TA-TMA) is a severe thrombotic complication that occurs after hematopoietic stem cell transplantation. Currently, there are no clear conclusions on the factors influencing the prognosis of TA-TMA patients and the best treatment plan for TA-TMA.</p><p><strong>Methods: </strong>We retrospectively collected information on 26 patients with TA-TMA from a single center. The independent factors affecting prognosis were analyzed through univariate and multivariate Cox regression. Subgroup analysis was also conducted to investigate the impact of different treatment methods on overall survival of patients.</p><p><strong>Results: </strong>We found that high creatinine levels during the diagnosis of TA-TMA and previous CAR-T cell therapy were independent risk factors affecting the prognosis of TA-TMA patients. Additionally, discontinuing calcineurin inhibitors (CNI) is helpful in prolonging the survival period of TA-TMA patients.</p><p><strong>Conclusions: </strong>Our research has revealed the high-risk factors affecting the survival of TA-TMA patients and the efficacy of different treatment methods, providing guidance for subsequent clinical practice.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"232"},"PeriodicalIF":3.2,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential therapeutic roles of natural killer cells in acute myeloid leukemia: a systematic review study.","authors":"Mohammad Khani-Eshratabadi, Jamal Motallebzadeh Khanmiri, Mohammad Reza Dashti, Sina Esmaeili, Zeinab Moradi Sani, Amirreza Daei, Mohaddeseh Hedayat Hasanabadi, Simin Saberi Amarghan, Nazanin Younesi Moghaddam, Behzad Baradaran","doi":"10.1007/s10238-025-01786-w","DOIUrl":"10.1007/s10238-025-01786-w","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a blood cancer caused by genetic mutations in hematopoietic precursor cells, leading to abnormal cell production in the bone marrow (BM) and results in complications like anemia, leukopenia, and thrombocytopenia. Treatments, such as chemotherapy and hematopoietic stem cell transplantation carry risks like graft-versus-host disease (GVHD) and infections due to immune suppression. Recently, treatment with natural killer (NK) cells has emerged as a novel approach for treating AML. NK cells can identify and destroy leukemic cells, and methods like NK cell transfer and cytokine activation show promise as effective treatments. This article evaluates the feasibility and safety of NK cell-based therapies for AML patients. This article is a systematic review that registered its protocol in PROSPERO. A strategic search was conducted in the PubMed, Scopus, Google Scholar, and Web of Science databases using the keywords \"Natural killer cell, \" \"Acute myeloid leukemia\" and \"Immunotherapy\". After removing duplicates and applying inclusion/exclusion criteria, 1623 articles were selected. Two reviewers screened titles and abstracts, followed by a full-text review. Disagreements were resolved by a third reviewer, resulting in 17 articles for inclusion. Data were organized in Excel, and study quality was assessed using the Cochrane risk-of-bias tool. Data analysis was performed using R software. Out of 1623 initially identified records, 17 clinical studies comprising 402 AML patients aged between 1 and 82 years were included. Most studies used allogeneic or homologous NK cells, sometimes combined with chemotherapy or interleukin-2. The pooled complete remission (CR) rate was 48.22% (95% CI 31.75-65.09%), with significant heterogeneity (I² = 76%). Immune response prevalence across 14 studies was 69.34% (95% CI 49.18-84.09%). Adverse events were generally mild and manageable, with no consistent reports of severe toxicity. Although study quality varied, eight studies demonstrated low risk of bias. Publication bias was detected for CR outcomes, adjusting the CR rate to 36.94% after correction. We conducted a systematic review that demonstrates that NK cell therapy shows promising efficacy and acceptable safety in treating AML patients, with a pooled complete remission rate of 48.22% and encouraging immune response rates. Despite heterogeneity across studies and varying methodological quality, the consistent observation of anti-leukemic effects and manageable adverse events supports the potential role of NK cell therapy as a complementary treatment. Further high-quality, large-scale trials are warranted to validate these findings and optimize clinical protocols.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"233"},"PeriodicalIF":3.2,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antitumor effects of human antithymocyte globulin on peripheral T cell lymphoma via complement-dependent and -independent cytotoxicity in xenograft mouse models.","authors":"Bei-Bei Gao, Tian-Qi Zhang, Jing-Jing Zhang, Hai-Na Wang, Dan Huang, Xue-Hong Zhang, Zhi-Jie Kang, Yan Yang, Xiao-Lan Liu, Chuang Sun, Jing Shao, Jin-Song Yan","doi":"10.1007/s10238-025-01726-8","DOIUrl":"10.1007/s10238-025-01726-8","url":null,"abstract":"<p><p>Peripheral T cell lymphomas (PTCL) is a group of non-Hodgkin lymphomas characterized by substantial molecular heterogeneity, rapid progression, poor therapeutic response, and unfavorable outcomes. In recent clinical studies, antithymocyte globulin (ATG)-based allogeneic hematopoietic stem cell transplantation (allo-HSCT) has markedly improved the prognosis and survival of patients with PTCL. This study aimed to explore whether ATG has toxic effects on PTCL cells and evaluate whether ATG combined with chemotherapy has a synergistic antitumor effect. Our research revealed that ATG significantly inhibited PTCL cell growth by suppressing cell proliferation and colony formation. Moreover, ATG treatment decreased cell invasion; however, it had no effect on cell cycle arrest in PTCL cells. ATG-induced PTCL cell apoptosis, which was partially reversed by pan-caspase inhibitor and caspase 8 inhibitor. Additionally, ATG was able to induce complement-dependent cytotoxicity in PTCL cells. Of note, the combination of ATG and doxorubicin exhibited an enhanced antitumor effect against PTCL in xenograft mouse models in vivo. The addition of ATG into the chemotherapy regimen may be a beneficial way for treating PTCL.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"231"},"PeriodicalIF":3.2,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunomodulatory properties of the gut microbiome: diagnostic and therapeutic potential for rheumatoid arthritis.","authors":"Desalegn Abebaw, Yibeltal Akelew, Adane Adugna, Bantayehu Addis Tegegne, Zigale Hibstu Teffera, Mekuriaw Belayneh, Abebe Fenta, Bantegzie Selabat, Yonatan Kindie, Temesgen Baylie, Muluken Getinet Mekuriaw, Mohammed Jemal, Aytenew Atnaf","doi":"10.1007/s10238-025-01777-x","DOIUrl":"10.1007/s10238-025-01777-x","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent joint inflammation, synovial hyperplasia, and progressive joint destruction. Despite advancements in biologic disease-modifying antirheumatic drugs (bDMARDs) and TNF-α blockers, many RA patients still require more effective treatment options. Although genetic and environmental factors play a role in RA development, recent studies have emphasized the influence of the gut microbiota on disease onset and progression. Dysbiosis, or an imbalance in the gut microbial composition, has been linked to immune dysregulation, increased intestinal permeability, and systemic inflammation, all contributing to RA development. Research has revealed changes in the gut microbiome of RA patients, including an increased prevalence of Prevotella copri and a decreased presence of beneficial microbes such as Bifidobacterium, Bacteroides, and Lactobacillus. RA patients exhibit altered metabolite profiles, with reduced levels of short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, which are linked to immune regulation and intestinal barrier function. Specific metabolites, such as L-arginine, phosphorylcholine, and arachidonic acid, have potential as RA biomarkers, with predictive value for diagnosis. Therapeutic approaches focusing on the microbiome, including probiotics, fecal microbiota transplantation, and traditional medicines, show promise in alleviating RA symptoms and regulating immune function. This review provides an updated overview of the immunomodulatory effects of the gut microbiome and explores its potential applications in the diagnosis and treatment of RA.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"226"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of serum tumor markers may indicate the progression of interstitial lung disease in Sjögren's syndrome patients: new roles for old friends.","authors":"Jiamin Song, Ronglin Gao, Fang Han, Jincheng Pu, Yuanyuan Liang, Yanqing Wang, Zhenzhen Wu, Shengnan Pan, Huihong Wu, Yuhang Sun, Kailong Lin, Jianping Tang, Xuan Wang","doi":"10.1007/s10238-025-01779-9","DOIUrl":"10.1007/s10238-025-01779-9","url":null,"abstract":"<p><p>A retrospective case-control study was designed to identify the characteristics and predictors of primary Sjögren's syndrome (pSS)-associated progressive fibrosing interstitial lung disease (ILD). Patients who diagnosed pSS-ILD were enrolled from Shanghai Tongji Hospital between January 1, 2015, and September 30, 2023. Relevant clinical data, including medical history, laboratory test results, and imaging findings, were collected at baseline. Progressive pulmonary fibrosis (PPF) was defined as established standard during one year of follow-up. Multiple linear regression was used to assess the relationship between tumor markers and ILD activity status. Characteristics associated with progression were determined by COX regression analysis. Kaplan-Meier survival analysis was employed to evaluate the predictive accuracy of the model. A total of 58 patients with pSS-ILD were included. The incidence of pleuritis and baseline levels of carbohydrate antigen 50 (CA50) were significantly higher in the pSS-PPF group. No significant differences were observed in arterial blood gas analysis, tumor marker levels, or CT scores at baseline. A negative correlation was found between cancer antigen 199 (CA199) levels and forced vital capacity, while carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125) levels were positively correlated with the severity of CT lesions. Cox regression analysis identified CEA and CA50 as significant predictors of pulmonary prognosis, and survival analysis indicated that elevated levels of CEA and CA50 were associated with disease progression. Serum tumor markers, such as CEA and CA50, may serve as potential indicators of radiographic progression and declines in lung function in pSS-ILD patients, possibly identifying individuals at higher risk of poor prognosis.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"229"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing artificial intelligence for detection of pancreatic cancer: a machine learning approach.","authors":"Babak Khorsand, Zeinab Hesami, Samira Alipour, Maryam Farmani, Hamidreza Houri","doi":"10.1007/s10238-025-01761-5","DOIUrl":"10.1007/s10238-025-01761-5","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic cancer (PC) is one of the most lethal malignancies, often presenting with nonspecific symptoms and a dismal prognosis. Despite advancements in treatments, the 5-year survival rate remains low, highlighting the urgent need for effective early diagnostic approaches.</p><p><strong>Methods: </strong>This study investigated the potential of an artificial intelligence (AI)-based approach to enhance diagnostic accuracy for PC by integrating diverse data, including clinical variables, laboratory results, and biomarkers such as two circulating microRNAs and two periodontal pathogens. A cohort of 123 PC patients and 120 matched non-cancer controls were used to train the machine learning (ML) models.</p><p><strong>Results: </strong>Findings indicated that new-onset diabetes, levels of miR-21 and miR-155 in blood, and loads of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans in the oral cavity were the most important predictors of PC. Among predictive models, the ensemble learning exhibited superior accuracy with an area under the curve (AUC) of 0.87, a sensitivity of 0.89, and a specificity of 0.86.</p><p><strong>Conclusion: </strong>This research highlights the promise of integrating AI techniques to improve early detection of PC using non-invasive biomarkers. However, further external validation in diverse and multinational cohorts is needed to confirm generalizability before clinical implementation. If validated, this approach could pave the way for personalized screening strategies.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"228"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations.","authors":"Mahdis Abdar Esfahani, Nazli Servatian, Ali Jihad Hemid Al-Athari, Elaf Salah Mehdi Khafaja, Hamideh Rahmani Seraji, Hamed Soleimani Samarkhazan","doi":"10.1007/s10238-025-01783-z","DOIUrl":"10.1007/s10238-025-01783-z","url":null,"abstract":"<p><p>The field of hematology has experienced a substantial evolution with the acknowledgment of epigenetic processes as essential factors in the development of hematological malignancies. This review article examines the influence of epigenetic alterations, namely DNA methylation and histone modifications, on the onset and advancement of conditions such as acute myeloid leukemia and myelodysplastic syndromes. We discuss how these epigenetic modifications lead to the deregulation of gene expression, eventually promoting leukemogenesis. The emergence of epigenetic therapies, such as DNA methyltransferase inhibitors (e.g., azacitidine and decitabine), histone deacetylase inhibitors (e.g., vorinostat and romidepsin), and enhancer of zeste homologue 2 inhibitors (e.g., tazmetostat), demonstrates the potential to reverse aberrant epigenetic modifications and restoring normal cellular functions. Moreover, we highlight innovative therapeutic approaches, including combination therapies and CRISPR-based epigenetic editing tools, which are influencing the future of treatment for hematological malignancies. Despite promising results, challenges such as off-target effects, drug resistance, and the need for personalized approaches remain significant barriers to effective treatment. We emphasize that further study is required to improve delivery systems, comprehend resistance mechanisms and develop precision medicine strategies that can tailor therapies to individual patient profiles. By integrating benchside discoveries with clinical applications, this review aims to illuminate the transformative potential of epigenetic therapies in improving patient outcomes in hematology.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"230"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying novel biomarkers for ankylosing spondylitis through proteomic profiling of serum-derived extracellular vesicles.","authors":"Soo-Eun Sung, Wook-Tae Park, Joo-Hee Choi, Young-In Kim, Min-Jung Ma, Wan-Suk Son, Sangbum Park, Ju-Hyeon Lim, Min-Soo Seo, Gun Woo Lee","doi":"10.1007/s10238-025-01718-8","DOIUrl":"10.1007/s10238-025-01718-8","url":null,"abstract":"<p><p>The objective of this study is to analyze the protein composition of extracellular vesicles (EVs) isolated from the serum of ankylosing spondylitis (AS) patients to identify potential biomarkers that could enable the early diagnosis and intervention of this condition. Serum samples were collected from AS patients and controls. EVs were isolated from these samples using ExoQuick® ULTRA solution, and their morphology, size, and concentration were analyzed using transmission electron microscopy and nanoparticle tracking analysis. Proteins within the EVs were identified and quantified through liquid chromatography-mass spectrometry (LC-MS/MS), followed by validation of key proteins using enzyme-linked immunosorbent assay (ELISA). Data were analyzed to identify proteins significantly upregulated in AS patients compared with the levels in controls. Here, through LC-MS/MS analysis, we demonstrated that Fibulin-1 (FBLN1), von Willebrand factor (VWF), complement factor H-related protein 2 (CFHR2), and lysozyme C (LYZ) expression were significantly upregulated in serum-derived EVs from AS patients compared with the levels in controls. These findings were further validated by ELISA, confirming the potential utility of serum-derived EVs as specific biomarkers for AS. The elevated levels of FBLN1, VWF, CFHR2, and LYZ in the EVs of AS patients represent promising candidates for biomarkers in the early diagnosis and treatment of AS. Further research should be performed to validate these findings and explore their clinical applicability.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"227"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SIRT1 as a masterful reciprocal regulator of molecular mechanisms and signaling pathways involved in tumor growth and expansion.","authors":"Mehrdad Hashemi, Neda Zali, Seyedeh Zahra Ghafarzadeh Dastjerdi, Bita Pakshad, Melika Aliahmadi, Nafiseh Sharifi, Kimia Sadat Esfahani, Fatemeh Sadat Kohandani, Sogand Chamanian, Fariba Abbasi, Faranak Jamshidian, Afshin Taheriazam, Mina Alimohammadi, Payman Rahimzadeh, Najma Farahani, Maliheh Entezari","doi":"10.1007/s10238-025-01759-z","DOIUrl":"10.1007/s10238-025-01759-z","url":null,"abstract":"<p><p>Sirtuin 1, which is more commonly identified as SIRT1, is a well-recognized NAD⁺-dependent histone and/or protein deacetylase that operates a wide range of cellular and molecular mechanisms involved in carcinogenic processes. SIRT1 not only regulates the primary mechanisms involved in tumorigenesis but also is responsible for controlling other processes, such as cell migration and metastasis, autophagy, and apoptotic flux, as well as chemotherapeutic resistance. It is well established that SIRT1 works at the upstream of signal transduction pathways, such as p53 signaling, together with FOXO mechanism, as well as the others. Indeed, SIRT1 by its deacetylase activity deacetylates different molecules in those signaling pathways and mostly causes a kind of blockade in the signaling of interest. Nonetheless, many aspects of SIRT1-cancer relationship are ambiguous, and more experiments should be performed for further uncovering of the concept. In the current review, we first highlight the major regulators of SIRT1 in cancer and then underscore key signal transduction pathways regulated by SIRT1. In the following, the role of SIRT1 will be discussed in tumor progression, from tumorigenesis to chemotherapeutic resistance, and at last, the contribution of SIRT1 to human cancers will be exemplified by some studies conducted in the field.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"225"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}